Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing care population.
Identifieur interne : 000A39 ( Main/Exploration ); précédent : 000A38; suivant : 000A40Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing care population.
Auteurs : Z. Hirji [Canada] ; S. O'Grady ; J. Bonham ; M. Mak ; J. Takata-Shewchuk ; K. Hawkins ; M. Gardam ; L. Law ; T. Mazzulli ; J. ConlySource :
- Infection control and hospital epidemiology [ 0899-823X ] ; 2002.
Descripteurs français
- KwdFr :
- Acides sialiques (effets indésirables), Acides sialiques (usage thérapeutique), Adulte d'âge moyen (MeSH), Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Capacité hospitalière de 500 lits et plus (MeSH), Centres de rééducation et de réadaptation (organisation et administration), Comorbidité (MeSH), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Guanidines (MeSH), Humains (MeSH), Hôpitaux urbains (organisation et administration), Infection croisée (prévention et contrôle), Infection croisée (traitement médicamenteux), Infection croisée (virologie), Mâle (MeSH), Ontario (MeSH), Prémédication (MeSH), Pyrannes (MeSH), Soins de longue durée (organisation et administration), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Sécurité (MeSH), Unités hospitalières (organisation et administration), Virus de la grippe A (isolement et purification), Virus influenza B (isolement et purification), Zanamivir (MeSH), Épidémies de maladies (prévention et contrôle).
- MESH :
- effets indésirables : Acides sialiques, Antiviraux.
- isolement et purification : Virus de la grippe A, Virus influenza B.
- organisation et administration : Centres de rééducation et de réadaptation, Hôpitaux urbains, Soins de longue durée, Unités hospitalières.
- prévention et contrôle : Grippe humaine, Infection croisée, Épidémies de maladies.
- traitement médicamenteux : Grippe humaine, Infection croisée.
- usage thérapeutique : Acides sialiques, Antiviraux.
- virologie : Grippe humaine, Infection croisée.
- Adulte d'âge moyen, Capacité hospitalière de 500 lits et plus, Comorbidité, Femelle, Guanidines, Humains, Mâle, Ontario, Prémédication, Pyrannes, Sujet âgé, Sujet âgé de 80 ans ou plus, Sécurité, Zanamivir.
English descriptors
- KwdEn :
- Aged (MeSH), Aged, 80 and over (MeSH), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Comorbidity (MeSH), Cross Infection (drug therapy), Cross Infection (prevention & control), Cross Infection (virology), Disease Outbreaks (prevention & control), Female (MeSH), Guanidines (MeSH), Hospital Bed Capacity, 500 and over (MeSH), Hospital Units (organization & administration), Hospitals, Urban (organization & administration), Humans (MeSH), Influenza A virus (isolation & purification), Influenza B virus (isolation & purification), Influenza, Human (drug therapy), Influenza, Human (prevention & control), Influenza, Human (virology), Long-Term Care (organization & administration), Male (MeSH), Middle Aged (MeSH), Ontario (MeSH), Premedication (MeSH), Pyrans (MeSH), Rehabilitation Centers (organization & administration), Safety (MeSH), Sialic Acids (adverse effects), Sialic Acids (therapeutic use), Zanamivir (MeSH).
- MESH :
- chemical , adverse effects : Antiviral Agents, Sialic Acids.
- chemical , therapeutic use : Antiviral Agents, Sialic Acids.
- geographic : Ontario, Pyrans, Zanamivir.
- drug therapy : Cross Infection, Influenza, Human.
- isolation & purification : Influenza A virus, Influenza B virus.
- organization & administration : Hospital Units, Hospitals, Urban, Long-Term Care, Rehabilitation Centers.
- prevention & control : Cross Infection, Disease Outbreaks, Influenza, Human.
- virology : Cross Infection, Influenza, Human.
- Aged, Aged, 80 and over, Comorbidity, Female, Guanidines, Hospital Bed Capacity, 500 and over, Humans, Male, Middle Aged, Premedication, Safety.
Abstract
OBJECTIVE
To describe compliance with and the safety and prophylactic efficacy of zanamivir among patients at risk of developing influenza-related complications after exposure to both influenza A and B viruses.
DESIGN
Nonrandomized trial using both historical and contemporaneous controls from ward populations within the same facility.
SETTING
A 547-bed urban hospital providing complex continuing care and rehabiltation.
PATIENTS
Fifty patients on a single ward concomitantly exposed to both influenza A and B during an influenza outbreak.
INTERVENTIONS
All patients were screened for symptoms of influenza and nasopharyngeal swabs were sent for viral culture prior to treatment (two oral inhalations [2 x 5 mg] twice daily for 5 days) or prophylaxis (two oral inhalations [2 x 5 mg] once daily for 14 days) with zanamivir. Patient symptoms, compliance, and drug tolerance were monitored daily. Demographic data, comorbidities, vaccination status, and functional status (Katz score) were collected for all patients.
RESULTS
The mean age of the patients was 70.6 years (standard deviation, +/- 16.4 years). Ninety-four percent had two or more comorbidities, 71% were dependent in two or more activities of daily living, 63% had been vaccinated for influenza, and 82% had received amantadine. Zanamivir was well tolerated, with 93% of the patients completing their course. The efficacy for preventing symptomatic infection was 82% and 91% (95% confidence interval, 62% to 98%) based on historical and contemporaneous controls, respectively.
CONCLUSION
These data suggest that zanamivir can be used safely and effectively as a prophylactic agent in the management of influenza outbreaks in a complex continuing care population with multiple comorbidities.
DOI: 10.1086/501979
PubMed: 12400891
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing care population.</title><author><name sortKey="Hirji, Z" sort="Hirji, Z" uniqKey="Hirji Z" first="Z" last="Hirji">Z. Hirji</name><affiliation wicri:level="1"><nlm:affiliation>The Riverdale Hospital, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Riverdale Hospital, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="O Grady, S" sort="O Grady, S" uniqKey="O Grady S" first="S" last="O'Grady">S. O'Grady</name></author><author><name sortKey="Bonham, J" sort="Bonham, J" uniqKey="Bonham J" first="J" last="Bonham">J. Bonham</name></author><author><name sortKey="Mak, M" sort="Mak, M" uniqKey="Mak M" first="M" last="Mak">M. Mak</name></author><author><name sortKey="Takata Shewchuk, J" sort="Takata Shewchuk, J" uniqKey="Takata Shewchuk J" first="J" last="Takata-Shewchuk">J. Takata-Shewchuk</name></author><author><name sortKey="Hawkins, K" sort="Hawkins, K" uniqKey="Hawkins K" first="K" last="Hawkins">K. Hawkins</name></author><author><name sortKey="Gardam, M" sort="Gardam, M" uniqKey="Gardam M" first="M" last="Gardam">M. Gardam</name></author><author><name sortKey="Law, L" sort="Law, L" uniqKey="Law L" first="L" last="Law">L. Law</name></author><author><name sortKey="Mazzulli, T" sort="Mazzulli, T" uniqKey="Mazzulli T" first="T" last="Mazzulli">T. Mazzulli</name></author><author><name sortKey="Conly, J" sort="Conly, J" uniqKey="Conly J" first="J" last="Conly">J. Conly</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12400891</idno><idno type="pmid">12400891</idno><idno type="doi">10.1086/501979</idno><idno type="wicri:Area/Main/Corpus">000A46</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000A46</idno><idno type="wicri:Area/Main/Curation">000A46</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000A46</idno><idno type="wicri:Area/Main/Exploration">000A46</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing care population.</title><author><name sortKey="Hirji, Z" sort="Hirji, Z" uniqKey="Hirji Z" first="Z" last="Hirji">Z. Hirji</name><affiliation wicri:level="1"><nlm:affiliation>The Riverdale Hospital, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Riverdale Hospital, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="O Grady, S" sort="O Grady, S" uniqKey="O Grady S" first="S" last="O'Grady">S. O'Grady</name></author><author><name sortKey="Bonham, J" sort="Bonham, J" uniqKey="Bonham J" first="J" last="Bonham">J. Bonham</name></author><author><name sortKey="Mak, M" sort="Mak, M" uniqKey="Mak M" first="M" last="Mak">M. Mak</name></author><author><name sortKey="Takata Shewchuk, J" sort="Takata Shewchuk, J" uniqKey="Takata Shewchuk J" first="J" last="Takata-Shewchuk">J. Takata-Shewchuk</name></author><author><name sortKey="Hawkins, K" sort="Hawkins, K" uniqKey="Hawkins K" first="K" last="Hawkins">K. Hawkins</name></author><author><name sortKey="Gardam, M" sort="Gardam, M" uniqKey="Gardam M" first="M" last="Gardam">M. Gardam</name></author><author><name sortKey="Law, L" sort="Law, L" uniqKey="Law L" first="L" last="Law">L. Law</name></author><author><name sortKey="Mazzulli, T" sort="Mazzulli, T" uniqKey="Mazzulli T" first="T" last="Mazzulli">T. Mazzulli</name></author><author><name sortKey="Conly, J" sort="Conly, J" uniqKey="Conly J" first="J" last="Conly">J. Conly</name></author></analytic><series><title level="j">Infection control and hospital epidemiology</title><idno type="ISSN">0899-823X</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Comorbidity (MeSH)</term><term>Cross Infection (drug therapy)</term><term>Cross Infection (prevention & control)</term><term>Cross Infection (virology)</term><term>Disease Outbreaks (prevention & control)</term><term>Female (MeSH)</term><term>Guanidines (MeSH)</term><term>Hospital Bed Capacity, 500 and over (MeSH)</term><term>Hospital Units (organization & administration)</term><term>Hospitals, Urban (organization & administration)</term><term>Humans (MeSH)</term><term>Influenza A virus (isolation & purification)</term><term>Influenza B virus (isolation & purification)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Long-Term Care (organization & administration)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Ontario (MeSH)</term><term>Premedication (MeSH)</term><term>Pyrans (MeSH)</term><term>Rehabilitation Centers (organization & administration)</term><term>Safety (MeSH)</term><term>Sialic Acids (adverse effects)</term><term>Sialic Acids (therapeutic use)</term><term>Zanamivir (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acides sialiques (effets indésirables)</term><term>Acides sialiques (usage thérapeutique)</term><term>Adulte d'âge moyen (MeSH)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Capacité hospitalière de 500 lits et plus (MeSH)</term><term>Centres de rééducation et de réadaptation (organisation et administration)</term><term>Comorbidité (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (virologie)</term><term>Guanidines (MeSH)</term><term>Humains (MeSH)</term><term>Hôpitaux urbains (organisation et administration)</term><term>Infection croisée (prévention et contrôle)</term><term>Infection croisée (traitement médicamenteux)</term><term>Infection croisée (virologie)</term><term>Mâle (MeSH)</term><term>Ontario (MeSH)</term><term>Prémédication (MeSH)</term><term>Pyrannes (MeSH)</term><term>Soins de longue durée (organisation et administration)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Sécurité (MeSH)</term><term>Unités hospitalières (organisation et administration)</term><term>Virus de la grippe A (isolement et purification)</term><term>Virus influenza B (isolement et purification)</term><term>Zanamivir (MeSH)</term><term>Épidémies de maladies (prévention et contrôle)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Sialic Acids</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Sialic Acids</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ontario</term><term>Pyrans</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cross Infection</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Acides sialiques</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Centres de rééducation et de réadaptation</term><term>Hôpitaux urbains</term><term>Soins de longue durée</term><term>Unités hospitalières</term></keywords><keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Hospital Units</term><term>Hospitals, Urban</term><term>Long-Term Care</term><term>Rehabilitation Centers</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cross Infection</term><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term><term>Infection croisée</term><term>Épidémies de maladies</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term><term>Infection croisée</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acides sialiques</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term><term>Infection croisée</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Cross Infection</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Comorbidity</term><term>Female</term><term>Guanidines</term><term>Hospital Bed Capacity, 500 and over</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Premedication</term><term>Safety</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Capacité hospitalière de 500 lits et plus</term><term>Comorbidité</term><term>Femelle</term><term>Guanidines</term><term>Humains</term><term>Mâle</term><term>Ontario</term><term>Prémédication</term><term>Pyrannes</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Sécurité</term><term>Zanamivir</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To describe compliance with and the safety and prophylactic efficacy of zanamivir among patients at risk of developing influenza-related complications after exposure to both influenza A and B viruses.</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN</b></p><p>Nonrandomized trial using both historical and contemporaneous controls from ward populations within the same facility.</p></div><div type="abstract" xml:lang="en"><p><b>SETTING</b></p><p>A 547-bed urban hospital providing complex continuing care and rehabiltation.</p></div><div type="abstract" xml:lang="en"><p><b>PATIENTS</b></p><p>Fifty patients on a single ward concomitantly exposed to both influenza A and B during an influenza outbreak.</p></div><div type="abstract" xml:lang="en"><p><b>INTERVENTIONS</b></p><p>All patients were screened for symptoms of influenza and nasopharyngeal swabs were sent for viral culture prior to treatment (two oral inhalations [2 x 5 mg] twice daily for 5 days) or prophylaxis (two oral inhalations [2 x 5 mg] once daily for 14 days) with zanamivir. Patient symptoms, compliance, and drug tolerance were monitored daily. Demographic data, comorbidities, vaccination status, and functional status (Katz score) were collected for all patients.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The mean age of the patients was 70.6 years (standard deviation, +/- 16.4 years). Ninety-four percent had two or more comorbidities, 71% were dependent in two or more activities of daily living, 63% had been vaccinated for influenza, and 82% had received amantadine. Zanamivir was well tolerated, with 93% of the patients completing their course. The efficacy for preventing symptomatic infection was 82% and 91% (95% confidence interval, 62% to 98%) based on historical and contemporaneous controls, respectively.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>These data suggest that zanamivir can be used safely and effectively as a prophylactic agent in the management of influenza outbreaks in a complex continuing care population with multiple comorbidities.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12400891</PMID><DateCompleted><Year>2003</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>01</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0899-823X</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>10</Issue><PubDate><Year>2002</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Infection control and hospital epidemiology</Title><ISOAbbreviation>Infect Control Hosp Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing care population.</ArticleTitle><Pagination><MedlinePgn>604-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe compliance with and the safety and prophylactic efficacy of zanamivir among patients at risk of developing influenza-related complications after exposure to both influenza A and B viruses.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Nonrandomized trial using both historical and contemporaneous controls from ward populations within the same facility.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">A 547-bed urban hospital providing complex continuing care and rehabiltation.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Fifty patients on a single ward concomitantly exposed to both influenza A and B during an influenza outbreak.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">All patients were screened for symptoms of influenza and nasopharyngeal swabs were sent for viral culture prior to treatment (two oral inhalations [2 x 5 mg] twice daily for 5 days) or prophylaxis (two oral inhalations [2 x 5 mg] once daily for 14 days) with zanamivir. Patient symptoms, compliance, and drug tolerance were monitored daily. Demographic data, comorbidities, vaccination status, and functional status (Katz score) were collected for all patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age of the patients was 70.6 years (standard deviation, +/- 16.4 years). Ninety-four percent had two or more comorbidities, 71% were dependent in two or more activities of daily living, 63% had been vaccinated for influenza, and 82% had received amantadine. Zanamivir was well tolerated, with 93% of the patients completing their course. The efficacy for preventing symptomatic infection was 82% and 91% (95% confidence interval, 62% to 98%) based on historical and contemporaneous controls, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data suggest that zanamivir can be used safely and effectively as a prophylactic agent in the management of influenza outbreaks in a complex continuing care population with multiple comorbidities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hirji</LastName><ForeName>Z</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Riverdale Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Grady</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bonham</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mak</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Takata-Shewchuk</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hawkins</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Gardam</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Law</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Mazzulli</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Conly</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Infect Control Hosp Epidemiol</MedlineTA><NlmUniqueID>8804099</NlmUniqueID><ISSNLinking>0899-823X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006146">Guanidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011714">Pyrans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012794">Sialic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>N</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Infect Control Hosp Epidemiol. 2002 Oct;23(10):564-7</RefSource><PMID Version="1">12400883</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003428" MajorTopicYN="N">Cross Infection</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006146" MajorTopicYN="N">Guanidines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006746" MajorTopicYN="N">Hospital Bed Capacity, 500 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006757" MajorTopicYN="N">Hospital Units</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization & administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006786" MajorTopicYN="N">Hospitals, Urban</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization & administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization & administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011292" MajorTopicYN="N">Premedication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011714" MajorTopicYN="N">Pyrans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012047" MajorTopicYN="N">Rehabilitation Centers</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization & administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012449" MajorTopicYN="N">Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012794" MajorTopicYN="N">Sialic Acids</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>10</Month><Day>29</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>2</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>10</Month><Day>29</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12400891</ArticleId><ArticleId IdType="pii">S0195941700081431</ArticleId><ArticleId IdType="doi">10.1086/501979</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Bonham, J" sort="Bonham, J" uniqKey="Bonham J" first="J" last="Bonham">J. Bonham</name><name sortKey="Conly, J" sort="Conly, J" uniqKey="Conly J" first="J" last="Conly">J. Conly</name><name sortKey="Gardam, M" sort="Gardam, M" uniqKey="Gardam M" first="M" last="Gardam">M. Gardam</name><name sortKey="Hawkins, K" sort="Hawkins, K" uniqKey="Hawkins K" first="K" last="Hawkins">K. Hawkins</name><name sortKey="Law, L" sort="Law, L" uniqKey="Law L" first="L" last="Law">L. Law</name><name sortKey="Mak, M" sort="Mak, M" uniqKey="Mak M" first="M" last="Mak">M. Mak</name><name sortKey="Mazzulli, T" sort="Mazzulli, T" uniqKey="Mazzulli T" first="T" last="Mazzulli">T. Mazzulli</name><name sortKey="O Grady, S" sort="O Grady, S" uniqKey="O Grady S" first="S" last="O'Grady">S. O'Grady</name><name sortKey="Takata Shewchuk, J" sort="Takata Shewchuk, J" uniqKey="Takata Shewchuk J" first="J" last="Takata-Shewchuk">J. Takata-Shewchuk</name></noCountry><country name="Canada"><noRegion><name sortKey="Hirji, Z" sort="Hirji, Z" uniqKey="Hirji Z" first="Z" last="Hirji">Z. Hirji</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A39 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A39 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:12400891
|texte= Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing care population.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12400891" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |